Merus (NASDAQ:MRUS) VP Sells $163,370.00 in Stock

Merus N.V. (NASDAQ:MRUS) VP Harry Shuman sold 1,700 shares of Merus stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $96.10, for a total value of $163,370.00. Following the sale, the vice president owned 11,002 shares in the company, valued at $1,057,292.20. This trade represents a 13.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Harry Shuman also recently made the following trade(s):

• On Tuesday, November 25th, Harry Shuman sold 8,300 shares of Merus stock. The stock was sold at an average price of $95.92, for a total transaction of $796,136.00.

Merus Stock Performance

NASDAQ MRUS traded up $0.41 during trading on Wednesday, reaching $96.77. The company’s stock had a trading volume of 3,132,743 shares, compared to its average volume of 1,281,310. The business’s fifty day moving average price is $95.26 and its 200-day moving average price is $73.73. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $96.83. The firm has a market cap of $7.34 billion, a price-to-earnings ratio of -18.26 and a beta of 1.06.

Wall Street Analyst Weigh In

MRUS has been the topic of several recent research reports. Industrial Alliance Securities set a $90.00 price objective on Merus in a research report on Monday, August 25th. Canaccord Genuity Group cut Merus from a “buy” rating to a “hold” rating and boosted their price target for the stock from $67.00 to $97.00 in a report on Monday, September 29th. William Blair downgraded Merus from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. HC Wainwright cut Merus from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $135.00 to $97.00 in a research report on Monday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Merus in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $93.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Merus during the 3rd quarter valued at $42,000. Farther Finance Advisors LLC grew its stake in shares of Merus by 10,400.0% during the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 520 shares in the last quarter. Longfellow Investment Management Co. LLC purchased a new stake in shares of Merus during the third quarter worth about $75,000. CWM LLC increased its position in shares of Merus by 299.0% during the second quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 601 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Merus in the third quarter worth about $114,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.